Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
Is there a general consensus on margins to use when treating SCCIS or BCC with ED&C?
Related Questions
What are your favorite strategies in fixing post-surgical depressions from facial flaps?
In what clinical scenarios do you consider pre- or post-treatment with Imiquimod for cutaneous melanoma?
What approach, or dosing interval, do you find is most effective reducing side effects of Hedgehog Inhibitors (i.e., vismodegib) for patients with numerous BCC?
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
How would you manage a scalp squamous cell carcinoma s/p Mohs with high risk features who underwent placental grafting to expedite the healing process?
When do you recommend SRT, if ever, for small SCCs and BCCs?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib?
